| Protocol | Description | Details |
| 0S-99-10 | Blood Collection in Patients with GI Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Heinz Josef Lenz
Staff Members:
Jiayi Jiang
Ramona Lujan
|
| 0S-00-15 | Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Heinz Josef Lenz
Staff Members:
Ramona Lujan
Taison Tran
|
| 3L-03-1 | A Phase II Study of Intra-Arterial Chemotherapy with Cisplatin and Mitomycin-C in Patients with Hepatocellular Carcinoma.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: No
Principal Investigator(s):
Syma Iqbal
Staff Members:
Jiayi Jiang
Noureddine Miloud
Ramona Lujan
|
| 3L-08-1 | A Phase I, Open-Label, Multi-Center, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33, a Recombinant Humanized Antibody to Glypican-3 Administered Weekly in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Immunotherapy
| Randomized: No
Principal Investigator(s):
Heinz Josef Lenz
Staff Members:
Carol Jones
San Aye
Susan Edwards
Taison Tran
Xiomara Menendez
|
| 3L-09-1 | GIDEON: Global Investigation of Therapeutic Decisions in Hepatocelluar Carcinoma and of its Treatment with Sorafenib
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: No
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Carol Jones
Mary Ordaz
Ramona Lujan
Taison Tran
|
| 3L-09-2 | A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Immunotherapy
| Randomized: No
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Jiayi Jiang
Mary Ordaz
Susan Edwards
Xiomara Menendez
|
| 0S-09-5 | A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid, or Islet Cell Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Immunotherapy
| Randomized: No
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Anayansi Miloud
Carol Jones
Grace Facio
Marissa Aldana
Mary Ordaz
Xiomara Menendez
|
| 0S-09-8 | Characterization of Focal Liver Lesions with SonoVue-Enhanced Ultrasound Imaging: A Phase III, Intra-Patient Comparative Study versus Unenhanced Ultrasound Imaging Using Histology or Combined Imaging/Clinical Data as Truth Standard.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Edward Grant
Staff Members:
|
| 3L-08-2 | A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation (STORM).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
San Aye
Taison Tran
|
| 3L-09-3 | A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Anti-Angiogenesis
Immunotherapy
| Randomized: Yes
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Mary Ordaz
Ramona Lujan
Taison Tran
|
